---
title: "Annovis Bio Announces Offering Of Shares And Warrants To Advance Buntanetap In AD; Stock Down"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/287040902.md"
description: "Annovis Bio, Inc. (ANVS) has announced a public offering of shares and warrants to fund the clinical development of its lead drug, Buntanetap, for Alzheimer's disease. The stock closed at $1.94, down 5.37%, and is down 18.77% in pre-market trading at $1.58."
datetime: "2026-05-20T09:45:19.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/287040902.md)
  - [en](https://longbridge.com/en/news/287040902.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/287040902.md)
---

# Annovis Bio Announces Offering Of Shares And Warrants To Advance Buntanetap In AD; Stock Down

(RTTNews) - Annovis Bio, Inc. (ANVS), a clinical-stage biotechnology firm that develops drugs to treat neurodegeneration, announces a public offering in which it intends to offer shares and accompanying warrants.

Annovis Bio develops treatments for Alzheimer's disease (AD) and Parkinson's disease. The firm's lead drug candidate, Buntanetap (formerly posiphen), is an investigational once-daily oral therapy.

Annovis intends to use the net proceeds from the offering for the continued clinical development of its lead compound Buntanetap in a Phase 3 study for Alzheimer's disease (AD), and for working capital and general corporate purposes.

ANVS has traded between $1.54 and $5.50 over the last year. The stock closed Tuesday's trade at $1.94, down 5.37%.

In the pre-market, ANVS is down 18.77% at $1.58.

For more such news For More Such Biotech Stock News, visit rttnews.com.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

### Related Stocks

- [ANVS.US](https://longbridge.com/en/quote/ANVS.US.md)
- [NDAQ.US](https://longbridge.com/en/quote/NDAQ.US.md)

## Related News & Research

- [Annovis Bio Regains NYSE Compliance Ahead Of 18-Month Cure Period](https://longbridge.com/en/news/287724562.md)
- [Cancer biotech Parabilis Medicines prices upsized IPO at $20, above the range](https://longbridge.com/en/news/289326488.md)
- [BUZZ-Enliven falls after $400 mln equity raise to fund leukemia drug](https://longbridge.com/en/news/289589890.md)
- [J&J to acquire Firefly, maker of ‘degrader’ antibody drugs, for $1B](https://longbridge.com/en/news/289312392.md)
- [Orviglance Data Presented Today at the Annual Radiology Congress ESGAR 2026](https://longbridge.com/en/news/289143345.md)